Literature DB >> 33490649

Establishment of a novel anti-TROP2 monoclonal antibody TrMab-29 for immunohistochemical analysis.

Yusuke Sayama1, Mika K Kaneko1, Junko Takei1, Hideki Hosono1, Masato Sano1, Teizo Asano1, Yukinari Kato1,2.   

Abstract

TROP2 is a type I transmembrane glycoprotein originally identified in pan class="Species">human trophoblast cells that is overexpressed in several types of cancer. To better understand the role of TROP2 in cancer, we herein aimed to develop a sensitive and specific anti-TROP2 monoclonal antibody (mAb) for use in flow cytometry, Western blot, and immunohistochemistry using a Cell-Based Immunization and Screening (CBIS) method. Two mice were immunized with N-terminal PA-tagged and C-terminal RAP/MAP-tagged TROP2-overexpressed Chinese hamster ovary (CHO)-K1 cells (CHO/PA-TROP2-RAP-MAP), and hybridomas showing strong signals from PA-tagged TROP2-overexpressed CHO-K1 cells (CHO/TROP2-PA) and weak-to-no signals from CHO-K1 cells were selected using flow cytometry. We demonstrated using flow cytometry that the established anti-TROP2 mAb, TrMab-29 (mouse IgG1 kappa), detected TROP2 in MCF7 breast cancer cell line as well as CHO/TROP2-PA cells. Western blot analysis showed a 40 kDa band in lysates prepared from both CHO/TROP2-PA and MCF7 cells. Furthermore, TROP2 was strongly detected by immunohistochemical analysis using TrMab-29, indicating that TrMab-29 may be a valuable tool for the detection of TROP2 in cancer.
© 2021 The Authors.

Entities:  

Keywords:  ADC, antibody-drug conjugates; ADCC, antibody-dependent cellular cytotoxicity; BSA, bovine serum albumin; Breast cancer; CAR-T, chimeric antigen receptor T-cell; CBIS method; CBIS, Cell-Based Immunization and Screening; CDC, complement-dependent cytotoxicity; CHO, Chinese hamster ovary; DAB, 3,3′-diaminobenzidine tetrahydrochloride; Monoclonal antibody; P3U1, P3X63Ag8U.1; PBS, phosphate-buffered saline; PIT, photoimmunotherapy; PVDF, polyvinylidene difluoride; RIT, radioimmunotherapy; TROP2; TROP2, trophoblast cell-surface antigen; mAb, monoclonal antibody

Year:  2021        PMID: 33490649      PMCID: PMC7806523          DOI: 10.1016/j.bbrep.2020.100902

Source DB:  PubMed          Journal:  Biochem Biophys Rep        ISSN: 2405-5808


  37 in total

1.  Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics.

Authors:  Andrew S Goldstein; Devon A Lawson; Donghui Cheng; Wenyi Sun; Isla P Garraway; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

2.  A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.

Authors:  Gentry T King; Keith D Eaton; Brandon R Beagle; Christopher J Zopf; Gilbert Y Wong; Heike I Krupka; Steven Y Hua; Wells A Messersmith; Anthony B El-Khoueiry
Journal:  Invest New Drugs       Date:  2018-01-15       Impact factor: 3.850

Review 3.  Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.

Authors:  Hidekazu Kawashima
Journal:  ScientificWorldJournal       Date:  2014-10-14

4.  Development of RAP Tag, a Novel Tagging System for Protein Detection and Purification.

Authors:  Yuki Fujii; Mika K Kaneko; Satoshi Ogasawara; Shinji Yamada; Miyuki Yanaka; Takuro Nakamura; Noriko Saidoh; Kanae Yoshida; Ryusuke Honma; Yukinari Kato
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2017-03-24

5.  Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.

Authors:  Mika K Kaneko; Takuro Nakamura; Ryusuke Honma; Satoshi Ogasawara; Yuki Fujii; Shinji Abe; Michiaki Takagi; Hiroyuki Harada; Hiroyoshi Suzuki; Yasuhiko Nishioka; Yukinari Kato
Journal:  Cancer Med       Date:  2017-01-19       Impact factor: 4.452

6.  Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C44Mab-5.

Authors:  Shinji Yamada; Shunsuke Itai; Takuro Nakamura; Miyuki Yanaka; Mika K Kaneko; Yukinari Kato
Journal:  Biochem Biophys Rep       Date:  2018-04-12

7.  Establishment of C20Mab-11, a novel anti-CD20 monoclonal antibody, for the detection of B cells.

Authors:  Yoshikazu Furusawa; Mika Kato Kaneko; Yukinari Kato
Journal:  Oncol Lett       Date:  2020-06-17       Impact factor: 2.967

Review 8.  Targeting Trop-2 in solid tumors: future prospects.

Authors:  Saif Zaman; Hassan Jadid; Aaron C Denson; Jhanelle E Gray
Journal:  Onco Targets Ther       Date:  2019-03-01       Impact factor: 4.147

9.  PMab-219: A monoclonal antibody for the immunohistochemical analysis of horse podoplanin.

Authors:  Yoshikazu Furusawa; Shinji Yamada; Shunsuke Itai; Takuro Nakamura; Miyuki Yanaka; Masato Sano; Hiroyuki Harada; Masato Fukui; Mika K Kaneko; Yukinari Kato
Journal:  Biochem Biophys Rep       Date:  2019-02-02

10.  Establishment of CMab-43, a Sensitive and Specific Anti-CD133 Monoclonal Antibody, for Immunohistochemistry.

Authors:  Shunsuke Itai; Yuki Fujii; Takuro Nakamura; Yao-Wen Chang; Miyuki Yanaka; Noriko Saidoh; Saori Handa; Hiroyoshi Suzuki; Hiroyuki Harada; Shinji Yamada; Mika K Kaneko; Yukinari Kato
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2017-09-14
View more
  3 in total

1.  Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications.

Authors:  Guanjie Li; Hiroyuki Suzuki; Teizo Asano; Tomohiro Tanaka; Hiroyoshi Suzuki; Mika K Kaneko; Yukinari Kato
Journal:  Antibodies (Basel)       Date:  2022-06-08

2.  Sacituzumab govitecan in triple-negative breast cancer.

Authors:  Alexandre de Nonneville; Anthony Goncalves; Emilie Mamessier; François Bertucci
Journal:  Ann Transl Med       Date:  2022-06

3.  Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.

Authors:  Teizo Asano; Tomokazu Ohishi; Junko Takei; Takuro Nakamura; Ren Nanamiya; Hideki Hosono; Tomohiro Tanaka; Masato Sano; Hiroyuki Harada; Manabu Kawada; Mika K Kaneko; Yukinari Kato
Journal:  Oncol Rep       Date:  2021-06-29       Impact factor: 3.906

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.